Zynerba stock rebounds after selloff driven by failed cannabis-based skin patch trial

Shares of Zynerba Pharmaceuticals Inc. rose 7% in Friday trade, recouping some of their prior-session losses that came after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals.


ZYNE, +6.00%

 , which is developing cannabis-based therapies for rare neurospsychiatric disorders, said the trial of ZYN001, which delivers tetrahydrocannabinol (THC) through a transdermal patch, did not achieve its goal of target blood levels of

... read more at: https://www.marketwatch.com/story/zynerba-stock-rebounds-after-selloff-driven-by-failed-cannabis-based-skin-patch-trial-2018-07-06